Eli Lilly and Company $LLY Shares Bought by First Trust Advisors LP

First Trust Advisors LP raised its position in Eli Lilly and Company (NYSE:LLY) by 0.8% in the 1st quarter, Holdings Channel reports. The fund owned 168,601 shares of the company’s stock after acquiring an additional 1,305 shares during the period. First Trust Advisors LP’s holdings in Eli Lilly and Company were worth $155,074,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of LLY. Chase Investment Counsel Corp purchased a new position in Eli Lilly and Company in the first quarter worth $281,000. Phillip James Consulting Co. purchased a new stake in shares of Eli Lilly and Company during the 1st quarter worth $190,000. Fortis Capital Management LLC grew its stake in shares of Eli Lilly and Company by 1.3% during the 1st quarter. Fortis Capital Management LLC now owns 8,839 shares of the company’s stock worth $8,130,000 after purchasing an additional 114 shares during the period. Meiji Yasuda America Inc increased its holdings in shares of Eli Lilly and Company by 2.8% in the 1st quarter. Meiji Yasuda America Inc now owns 11,072 shares of the company’s stock valued at $10,184,000 after purchasing an additional 304 shares in the last quarter. Finally, Temasek Holdings Private Ltd increased its holdings in shares of Eli Lilly and Company by 47.0% in the 1st quarter. Temasek Holdings Private Ltd now owns 173,259 shares of the company’s stock valued at $159,358,000 after purchasing an additional 55,412 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,185.31 on Friday. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The business has a 50 day simple moving average of $1,132.74 and a 200-day simple moving average of $1,039.05. The company has a market capitalization of $1.12 trillion, a price-to-earnings ratio of 42.11, a price-to-earnings-growth ratio of 1.47 and a beta of 0.51. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the previous year, the business earned $3.34 EPS. The firm’s revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 34.21 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s payout ratio is presently 24.58%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Leerink Partners raised their target price on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Wall Street Zen lowered Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Royal Bank Of Canada raised their price objective on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an “outperform” rating in a report on Wednesday, July 8th. The Goldman Sachs Group restated a “buy” rating and issued a $1,283.00 price target on shares of Eli Lilly and Company in a report on Friday, May 22nd. Finally, Cantor Fitzgerald raised their target price on shares of Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the stock an “overweight” rating in a research report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,283.64.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Retatrutide met its primary endpoints in two additional Phase 3 trials, with patients losing up to about 20.8% to 22.6% of body weight, strengthening the case for a highly valuable new obesity franchise. Reuters: Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application
• Positive Sentiment: Lilly said it now plans to file for FDA approval in the first quarter of 2027, keeping the drug on track for a potential future launch even though the filing was pushed back. CNBC: Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
• Neutral Sentiment: Lilly is also expanding its pipeline through the acquisition of AtaiBeckley, a psychedelic medicine biotech, which could support longer-term diversification but is not an immediate earnings driver. Motley Fool: Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here’s What You Need to Know.
• Negative Sentiment: The FDA filing for retatrutide was delayed from an earlier timeline, and Lilly said it needs more manufacturing and quality-control data, which adds a modest regulatory timing risk. Yahoo Finance: Lilly to file for next-gen obesity drug approval in early 2027
• Negative Sentiment: Novo Nordisk has filed a lawsuit accusing Lilly of misleading weight-loss advertising, creating headline legal risk in the competitive obesity-drug market. Yahoo Finance: How Novo Nordisk’s GLP-1 Advertising Lawsuit Against Eli Lilly (LLY) Has Changed Its Investment Story

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.